A Phase 1b/2a trial of ZP9830
Latest Information Update: 06 Mar 2026
At a glance
- Drugs ZP 9830 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
Most Recent Events
- 06 Mar 2026 New trial record
- 19 Feb 2026 According to Zealand Pharma media release, the trial is expected to initiate in the second half of 2026